Cancer drug olaparib gets a makeover: which pill works best?
NCT ID NCT00777582
First seen Jan 15, 2026 · Last updated Jun 19, 2026 · Updated 28 times
Summary
This phase I trial tests two different oral forms of the cancer drug olaparib (AZD2281) in people with advanced solid tumors that have not responded to standard treatments. The main goal is to see how well the body absorbs each form. About 197 participants will receive both forms in a random order to compare their bioavailability and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Randwick, 2031, Australia
-
Research Site
Leuven, 3000, Belgium
-
Research Site
Bellinzona, CH-6500, Switzerland
-
Research Site
Edinburgh, EH4 2XR, United Kingdom
-
Research Site
London, NW1 2PG, United Kingdom
-
Research Site
Manchester, M20 4BX, United Kingdom
-
Research Site
Newcastle upon Tyne, NE7 7DN, United Kingdom
-
Research Site
Northwood, HA6 2RN, United Kingdom
-
Research Site
Oxford, OX3 7LE, United Kingdom
-
Research Site
Sutton, SM2 5PT, United Kingdom
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Olaparib (AZD2281)
What this could lead to
If successful, this could help identify the best oral form of olaparib for future use in cancer treatment.
What could go wrong
This is an early-phase trial focused on drug absorption, not on curing cancer. Results may not lead to improved outcomes for patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.